0.6385
Pavmed Inc Borsa (PAVM) Ultime notizie
PAVmed (NASDAQ:PAVM) Given New $19.00 Price Target at Ascendiant Capital Markets - Defense World
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - MSN
PAVM: Ascendiant Capital Maintains Buy Rating but Lowers Price Target | PAVM Stock News - GuruFocus
PAVmed subsidiary Veris Health partners with Ohio State University cancer center - Yahoo Finance
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnersh - GuruFocus
PAVM Subsidiary Veris Health Partners with OSUCCC -- James for Cancer Care Innovations | PAVM Stock News - GuruFocus
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital and Solove Research Institute | PAVM Sto - GuruFocus
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com UK
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification - Yahoo Finance
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings - TipRanks
PAVmed Q1 2025 slides: net income soars amid strategic restructuring By Investing.com - Investing.com India
PAVmed Q1 2025 slides: net income soars amid strategic restructuring - Investing.com
Earnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shifts - Investing.com Nigeria
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Reports Q1 2025 Financial Results and Updates - TipRanks
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed (PAVM) Q1 Earnings Beat with Improved EPS and Revenue - GuruFocus
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports First Qua - GuruFocus
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - StreetInsider
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Finansavisen
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
PAVmed to Hold a Business Update Conference Call and Webcast on - GuruFocus
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - The Victoria Advocate
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 | PAVM Stock News - GuruFocus
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
Lucid Diagnostics to Reveal Q1 2025 Financial Results and Growth StrategyKey Details for Investors - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for PAVmed (NASDAQ:PAVM) Stock - The AM Reporter
PAVmed (NASDAQ:PAVM) Price Target Raised to $19.50 at Ascendiant Capital Markets - Defense World
PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - ADVFN
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):